NYU Langone Health Joined CLARITY Trial Network
The medical center has become the eleventh clinical site in a study evaluating the Nociscan diagnostic platform.
Updated on Sept. 29, 2026 in Alzheimer’s
Live Poll
Do you believe new diagnostic technologies are effectively improving treatment outcomes for chronic pain patients?
Aclarion announced on September 29, 2026, that NYU Langone Health is now participating in its CLARITY clinical trial. The study evaluates the Nociscan software-as-a-service platform, which uses augmented intelligence and magnetic resonance spectroscopy to identify sources of chronic low back pain.
Why it matters
The study aims to establish the clinical and economic value of Nociscan in guiding spine surgery decisions. By providing objective data on pain sources, the trial seeks to validate the platform as a standard for treating degenerative spine conditions.
The CLARITY trial evaluates 300 patients across 11 total research sites to assess the diagnostic accuracy of Nociscan. Nociscan utilizes magnetic resonance spectroscopy data to quantify chemical biomarkers associated with disc pain.
The players
Aclarion
A healthcare technology company based in Broomfield, Colorado, that specializes in AI-driven diagnostics for spine pain.
NYU Langone Health
A world-class academic medical center in New York City that operates a comprehensive spine center and manages extensive clinical research initiatives.
The details
Nociscan receives data from an MRI machine via a cloud connection to identify specific pain sources. The NYU Langone Spine Center, which serves more than 25,000 patients and performs over 4,700 surgical procedures annually, will now contribute data to this research effort.
Timeline
Aclarion announced the addition of the new trial site on September 29, 2026.
The Big Picture
The addition of NYU Langone Health to the CLARITY trial marks a significant expansion for the study. This move follows a pattern set by the CLARITY trial to integrate advanced diagnostic software into high-volume clinical workflows.
Patients at NYU Langone Health may now gain access to the Nociscan diagnostic platform during the course of the clinical study. This technology aims to provide clearer insights into the source of chronic back pain, potentially leading to more targeted treatment plans.
The takeaway
The incorporation of augmented intelligence in spine diagnostics represents a push toward more objective surgical assessments. Patients suffering from chronic back pain can benefit from emerging technologies that quantify chemical biomarkers to improve treatment accuracy.
Further reading
Learn more about the latest research in the Alzheimer’s section.
More information
View full CLARITY trial information and site map on the company's official portal.
Live Poll
Do you believe new diagnostic technologies are effectively improving treatment outcomes for chronic pain patients?
